Ruxolitinib and half-matched transplant for severe sickle cell disease
Treatments studied
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This trial tests a new approach using the drug ruxolitinib to help a half-matched bone marrow transplant work better for people with severe sickle cell disease. It aims to reduce complications and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 12 and 45 years old and have sickle cell disease.
- You have had a stroke, repeated severe chest pain (acute chest syndrome), or frequent pain crises needing hospital care.
- You have a parent, sibling, or half-sibling who is willing to donate bone marrow and is a half-match (haploidentical).
- You do not have a perfect match (full sibling) donor available.
- You are generally healthy enough for a bone marrow transplant (no active infections, previous transplant, or certain cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a half-matched (haploidentical) blood stem cell transplant can treat adults with severe sickle cell disease. It may help reduce serious complications and improve survival, but it requires a fit health status and specific donor and medical conditions.
This early-phase study tests whether a “half-matched” donor bone marrow transplant, with special medicines to calm the immune system before transplant, can improve outcomes for people with sickle cell disease. It may help high-risk patients who have frequent complications and don’t have a fully matched donor.
This Phase 2 study tests a “half-matched” stem cell transplant to treat people with aggressive sickle cell disease. It may help by replacing the blood system using stem cells from a related donor who is close but not fully matched.
This trial tests whether a stem cell transplant from a partially gene-matched family member can cure severe sickle cell disease in children and young adults. The transplant uses a new approach that may work even when a perfectly matched sibling isn't available, and it might help patients whose sickle cell is causing serious complications like strokes, organ damage, or frequent pain crises.
This trial tests a stem cell transplant from a half-matched donor using a strong conditioning regimen and a drug called defibrotide to protect organs. It aims to cure sickle cell disease in patients who have had serious complications like stroke, chest syndrome, or frequent pain episodes.
This trial tests whether a stem cell transplant from a fully matched sibling donor can help people with serious blood disorders like sickle cell disease or thalassemia. It aims to replace the faulty blood system with a healthy one from the donor.
Hear when a new Sickle Cell Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.